Papers/PMID:30835327
Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.
Cardiology journal2019The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
coenzyme Q10 — decreases all-cause mortality
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.Finding“All-cause mortality was lower in the CoQ10 group, 10 (9%) patients vs. 24 (20%) patients in the placebo group, corresponding to a relative reduction of 53% (p = 0.040).”
Quoted verbatim from Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.. - Study
- RCT
- Dose
- CoQ10 (Ubiquinone) 300 mg/day added to standard heart failure therapy
- Population
- European sub-population (n=231) of the Q-SYMBIO trial, moderate-to-severe chronic heart failure, on standard HF therapy in both arms, long-term (2-year) follow-up
Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.2019PMID:30835327Permalink